At the $15 midpoint, the firm expects net proceeds to reach $320.3 million, a figure that could climb to $369.1 million if underwriters exercise their option to purchase an additional 3.5 million shares. These funds, combined with existing capital, are intended to support the company’s operations through 2028 as it advances treatments for cardiovascular diseases currently lacking approved therapies.

Following the offering, the company will have approximately 91.2 million shares outstanding, assuming the overallotment option is fully utilized. This structure positions the business for a market capitalization of roughly $1.37 billion. Kardigan has filed to trade under the ticker symbol KARD.